[Federal Register Volume 77, Number 182 (Wednesday, September 19, 2012)]
[Notices]
[Pages 58213-58215]
[FR Doc No: 2012-22783]

-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Pipeline and Hazardous Materials Safety Administration

Actions on Special Permit Applications

AGENCY: Pipeline and Hazardous Materials Safety Administration (PHMSA),
DOT.

ACTION: Notice of actions on Special Permit Applications.

-----------------------------------------------------------------------

SUMMARY: In accordance with the procedures governing the application
for, and the processing of, special permits from the Department of

Transportation's Hazardous Material Regulations (49 CFR Part 107,
Subpart B), notice is hereby given of the actions on special permits
applications in (August to August 2012). The mode of transportation
involved are identified by a number in the ``Nature of Application''
portion of the table below as follows: 1--Motor vehicle, 2--Rail
freight, 3--Cargo vessel, 4--Cargo aircraft only, 5--Passenger-carrying
aircraft. Application numbers prefixed by the letters EE represent
applications for Emergency Special Permits. It should be noted that
some of the sections cited were those in effect at the time certain
special permits were issued.

    Issued in Washington, DC, on September 10, 2012.
Donald Burger,
Chief, Special Permits and Approvals Branch.

------------------------------------------------------------------------
                                                      Nature of special
    S.P. No.         Applicant      Regulation(s)      permit thereof
------------------------------------------------------------------------
                   Modification Special Permit Granted
------------------------------------------------------------------------
14298-M.........  Air Products     49 CFR           To modify the
                   and Chemicals,   180.209(a) and   special permit to
                   Inc.,            (b).             authorize an
                   Allentown, PA.                    additional Division
                                                     2.1 hazardous
                                                     material, to
                                                     increase maximum
                                                     acceptance flaw
                                                     size used on UE
                                                     requalification and
                                                     other miscellaneous
                                                     revisions.
12516-M.........  Poly-Coat        49 CFR           To modify the
                   Systems, Inc.,   107.503(b)(c);   special permit that
                   Liverpool, TX.   172.102(c)(3)    authorizes the
                                    B15 and 823;     manufacture, mark,
                                    173.241;         sale and use of non-
                                    173.242;         DOT specification
                                    178.345-1; -2;   cargo tanks
                                    -3; -4; -7; -    constructed of
                                    14; -15;         fiberglass
                                    178.347-1; -2;   reinforced plastic
                                    178.348-1;       by increasing the
                                    178.348-2;       volumetric
                                    180.405;         capacity.
                                    180.413(d).
------------------------------------------------------------------------
                       New Special Permit Granted
------------------------------------------------------------------------
15610-N.........  WavesinSolids    49 CFR 180.209,  To authorize the
                   LLC, State       180.209(a),      transportation in
                   College, PA.     180.205(c)(f)(   commerce of certain
                                    g) (i),          gases in DOT 3A,
                                    173.302a         3AA, 3AX, 3AAX and
                                    (b)(2)(3)(4)(5   3T cylinders. The
                                    ), 180.213,      cylinders (tubes)
                                    180.519(a),      are retested by
                                    180.519(b)(c).   acoustic emission
                                                     and ultrasonic
                                                     examination (AE/UE)
                                                     described in
                                                     paragraph 7 below
                                                     in place of the
                                                     internal visual
                                                     inspection and the
                                                     hydrostatic retest
                                                     required in Sec.
                                                     180.205. (modes 1,
                                                     2, 3)
15568-N.........  ATK Launch       49 CFR           To authorize the
                   Systems          172.101(b).      transportation in
                   Corinne, UT.                      commerce soils
                                                     containing solid
                                                     explosive compounds
                                                     (not greater than
                                                     3%) in bulk. (mode
                                                     1)
15577-N.........  Olin             49 CFR 172.101   To authorize the
                   Corporation      column 8,        tansportation in
                   Oxford, MS.      173.62(b),       commerce of certain
                                    173.60(b)(8),    Division 1.4 in non-
                                    172.300(d).      DOT specification
                                                     packagings without
                                                     labels and markings
                                                     to a distance not
                                                     to exceed 200 yards
                                                     by motor vehicle,
                                                     subject to the
                                                     limitations and
                                                     special
                                                     requirements
                                                     specified herein.
                                                     (modes 1, 2)
15623-N.........  Ledwell & Son    49 CFR 173.202,  To authorize the
                   Enterprises,     173.203,         manufacture,
                   Inc.,            173.241,         marking, sale and
                   Texarkana, TX.   173.242.         use of multiple non-
                                                     DOT specification
                                                     containers,
                                                     manifolded together
                                                     within a frame and
                                                     securely mounted on
                                                     a truck chassis,
                                                     for the
                                                     transportation in
                                                     commerce of the
                                                     materials
                                                     authorized by this
                                                     special permit.
                                                     (mode 1)
15654-N.........  T. SCOTT DUNN    49 CFR 172.101   To authorize the
                   CONSTRUCTION,    Column (9B),     transportation in
                   INC. DBA, Heli-  172.204(c)(3),   commerce of certain
                   Dunn, Phoenix,   173.27(b)(2),    hazardous materials
                   OR.              172.200,         by cargo only
                                    172.300, Part    aircraft and 14 CFR
                                    173, 175.30(a)   Part 133 Rotorcraft
                                    (1) and 175.75.  External Load
                                                     Operations
                                                     transporting
                                                     hazardous materials
                                                     attached to or
                                                     suspended from an
                                                     aircraft, in remote
                                                     areas of the US
                                                     only, without being
                                                     subject to hazard
                                                     communication
                                                     requirements,
                                                     quantity
                                                     limitations and
                                                     certain loading and
                                                     stowage
                                                     requirements. (mode
                                                     4)
15636-N.........  Ward Air, Inc.,  49 CFR 172.101   To authorize the
                   Juneau, AK.      Column (9B).     transportation in
                                                     commerce of certain
                                                     Class 1 explosive
                                                     materials which are
                                                     forbidden for
                                                     transportation by
                                                     air, to be
                                                     transported by
                                                     cargo aircraft
                                                     within the State of
                                                     Alaska when other
                                                     means of
                                                     transportation are
                                                     impracticable or
                                                     not available.
                                                     (mode 4)
15631-N.........  Atlas Air, Inc.  49 CFR 172.101   To authorize the
                   Miami, FL.       Column (9B),     transportation in
                                    172.204(c)(3),   commerce of
                                    173.27(b)(2)(3   Division 1.1
                                    ).               explosives, which
                                                     are forbidden, by
                                                     cargo-only
                                                     aircraft. (mode 4)
------------------------------------------------------------------------
                    Emergency Special Permit Granted
------------------------------------------------------------------------
15647-N.........  Thunderbird      49 CFR 179.7     To authorize
                   Cylinder,        and 180.505.     retesting of
                   Inc., Phoenix,                    certain DOT
                   AZ.                               Specification and
                                                     non-DOT
                                                     Specification multi
                                                     unit tank car
                                                     tanks. (modes 1,
                                                     2).
15637-N.........  Textron Inc.,    49 CFR 172.101   To authorize the
                   Wilmington, MA.  Column (9B),     transportation in
                                    172.204(c)(3),   commerce of
                                    173.27(b)(2)(3   Division 1.1
                                    ).               explosives, which
                                                     are forbidden, by
                                                     cargo-only
                                                     aircraft. (mode 4)
15664-N.........  Pollux Aviation  49 CFR 172.101   To authorize the
                   Ltd., Wasilla,   Column (9B);     transportation in
                   AK.              175.30(a)(1).    commerce of
                                                     liquefied petroleum
                                                     gas in amounts that
                                                     exceed the quantity
                                                     limitations for
                                                     transportation by
                                                     14 CFR Part 133
                                                     Rotorcraft External
                                                     Load Operations
                                                     transporting
                                                     hazardous materials
                                                     attached to or
                                                     suspended from an
                                                     aircraft only in
                                                     the State of
                                                     Alaska. (mode 4)

15677-N.........  Arkema, Inc.,    49 CFR           To authorize the
                   King of          173.304(b).      transportation in
                   Prussia, PA.                      PA commerce of DOT
                                                     Specification 39
                                                     thirty pound
                                                     cylinders by
                                                     highway, which have
                                                     the potential to
                                                     react during
                                                     transportation.
                                                     (mode 1)
15689-N.........  AVL Test         49 CFR 172.200,  To authorize the
                   Systems Inc.,    177.834.         discharge of a
                   Plymouth, MI.                     Division 2.1
                                                     material from an
                                                     authorized DOT
                                                     specification
                                                     cylinder without
                                                     removing the
                                                     cylinder from the
                                                     vehicle on which it
                                                     is transported.
                                                     (mode 1)
15685-N.........  National Air     49 CFR 172.101   To authorize the
                   Cargo Group,     Column (9B);     transportation in
                   Inc. dba,        172.204(c)(3);   commerce by cargo
                   National         173.27(b)(2)(3   only aircraft of
                   Airlines,        ); 175.30.       Class 1 explosives
                   Ypsilanti, MI.                    which are forbidden
                                                     or exceed
                                                     quantities
                                                     presently
                                                     authorized. (mode
                                                     4)
15696-N.........  Lantis           49 CFR 172.300,  To authorize the one-
                   Fireworks and    172.400 and      time, one-way
                   Lasers,          173.56.          transportation in
                   Draper, UT.                       commerce of 2142 kg
                                                     of unapproved
                                                     fireworks from
                                                     Carson, CA to the
                                                     Lantis Fireworks &
                                                     Lasers facility in
                                                     Fairfield, UT for
                                                     destruction by
                                                     motor vehicle.
                                                     (mode 1)
------------------------------------------------------------------------
                   Emergency Special Permit Withdrawn
------------------------------------------------------------------------
15670-N.........  Volga-Dnepr      49 CFR 172.101   To authorize the one-
                   Airlines,        Column (9B),     time transportation
                   Ulyanovsk.       172.204(c)(3),   in commerce of
                                    173.27, and      certain Division
                                    175.30(a)(1).    1.2 explosives that
                                                     are forbidden for
                                                     transportation by
                                                     cargo only
                                                     aircraft. (mode 4)
15682-N.........  Kalitta Air,     49 CFR 172.101   To authorize the one-
                   LLC,             Column (9B);     time transportation
                   Ypsilanti, MI.   172.204(c)(3);   in commerce of
                                    173.27(b)(2)(3   certain explosives
                                    );               that are forbidden
                                    175.30(a)(1).    for transportation
                                                     by cargo only
                                                     aircraft.
------------------------------------------------------------------------
                                 Denied
------------------------------------------------------------------------
15080-N.........     Request by Alaska Airlines Seattle, WA August 27,
                    2012. To authorize the transportation in commerce of
                     cylinders containing oxidizing gases without rigid
                    outer packagings without outer packaging capable of
                   passing the Flame Penetration and Resistance Test and
                    the Thermal Resistance Test when no other practical
                               means of transportation exist.
------------------------------------------------------------------------
                                 Denied
------------------------------------------------------------------------
10964-M.........  Request by Kidde Aerospace & Defense Wilson, NC August
                    1, 2012. To modify the permit to authorize a rework
                      procedure to allow fire extinguishers which were
                    ``steel stamped'' to be returned to within original
                                      specifications.
------------------------------------------------------------------------

[FR Doc. 2012-22783 Filed 9-18-12; 8:45 am]
BILLING CODE 4909-60-M


[Federal Register Volume 81, Number 250 (Thursday, December 29, 2016)]
[Notices]
[Pages 96168-96174]
[FR Doc No: 2016-31546]

-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Federal Motor Carrier Safety Administration

[Docket No. FMCSA-2016-0381]

Qualification of Drivers; Exemption Applications; Diabetes
Mellitus

AGENCY: Federal Motor Carrier Safety Administration (FMCSA), Department
of Transportation.

ACTION: Notice of applications for exemptions; request for comments.

-----------------------------------------------------------------------

SUMMARY: FMCSA announces receipt of applications from 41 individuals
for exemption from the prohibition against persons with insulin-treated
diabetes mellitus (ITDM) operating commercial motor vehicles (CMVs) in
interstate commerce. If granted, the exemptions would enable these
individuals with ITDM to operate CMVs in interstate commerce.

DATES: Comments must be received on or before January 30, 2017.

ADDRESSES: You may submit comments bearing the Federal Docket
Management System (FDMS) Docket No. FMCSA-2016-0381 using any of the
following methods:
     Federal eRulemaking Portal: Go to http://www.regulations.gov. Follow the on-line instructions for submitting
comments.
     Mail: Docket Management Facility; U.S. Department of
Transportation, 1200 New Jersey Avenue SE., West Building Ground Floor,
Room W12-140, Washington, DC 20590-0001.
     Hand Delivery: West Building Ground Floor, Room W12-140,
1200

New Jersey Avenue SE., Washington, DC, between 9 a.m. and 5 p.m., e.t.,
Monday through Friday, except Federal Holidays.
     Fax: 1-202-493-2251.
    Instructions: Each submission must include the Agency name and the
docket numbers for this notice. Note that all comments received will be
posted without change to http://www.regulations.gov, including any
personal information provided. Please see the Privacy Act heading below
for further information.
    Docket: For access to the docket to read background documents or
comments, go to http://www.regulations.gov at any time or Room W12-140
on the ground level of the West Building, 1200 New Jersey Avenue SE.,
Washington, DC, between 9 a.m. and 5 p.m., e.t., Monday through Friday,
except Federal holidays. The Federal Docket Management System (FDMS) is
available 24 hours each day, 365 days each year. If you want
acknowledgment that we received your comments, please include a self-
addressed, stamped envelope or postcard or print the acknowledgement
page that appears after submitting comments on-line.
    Privacy Act: In accordance with 5 U.S.C. 553(c), DOT solicits
comments from the public to better inform its rulemaking process. DOT
posts these comments, without edit, including any personal information
the commenter provides, to www.regulations.gov, as described in the
system of records notice (DOT/ALL-14 FDMS), which can be reviewed at
www.dot.gov/privacy.

FOR FURTHER INFORMATION CONTACT: Ms. Christine A. Hydock, Chief,
Medical Programs Division,<PHONE_NUMBER><EMAIL_ADDRESS>FMCSA,
Department of Transportation, 1200 New Jersey Avenue SE., Room W64-113,
Washington, DC 20590-0001. Office hours are 8:30 a.m. to 5 p.m., e.t.,
Monday through Friday, except Federal holidays.

SUPPLEMENTARY INFORMATION:

I. Background

    Under 49 U.S.C. 31136(e) and 31315, FMCSA may grant an exemption
from the Federal Motor Carrier Safety Regulations for a 2-year period
if it finds ``such exemption would likely achieve a level of safety
that is equivalent to or greater than the level that would be achieved
absent such exemption.'' The statute also allows the Agency to renew
exemptions at the end of the 2-year period. The 41 individuals listed
in this notice have recently requested such an exemption from the
diabetes prohibition in 49 CFR 391.41(b)(3), which applies to drivers
of CMVs in interstate commerce. Accordingly, the Agency will evaluate
the qualifications of each applicant to determine whether granting the
exemption will achieve the required level of safety mandated by
statute.

II. Qualifications of Applicants

Donald Austin

    Mr. Austin, 63, has had ITDM since 2012. His endocrinologist
examined him in 2016 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Austin understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Austin meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2016 and certified that he does not have
diabetic retinopathy. He holds a Class A CDL from Georgia.

Estil L. Baker, Jr.

    Mr. Baker, 58, has had ITDM since 2016. His endocrinologist
examined him in 2016 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Baker understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Baker meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2016 and certified that he does not have
diabetic retinopathy. He holds a Class A CDL from Illinois.

Thomas M. Bard

    Mr. Bard, 41, has had ITDM since 2016. His endocrinologist examined
him in 2016 and certified that he has had no severe hypoglycemic
reactions resulting in loss of consciousness, requiring the assistance
of another person, or resulting in impaired cognitive function that
occurred without warning in the past 12 months and no recurrent (2 or
more) severe hypoglycemic episodes in the last 5 years. His
endocrinologist certifies that Mr. Bard understands diabetes management
and monitoring, has stable control of his diabetes using insulin, and
is able to drive a CMV safely. Mr. Bard meets the requirements of the
vision standard at 49 CFR 391.41(b)(10). His optometrist examined him
in 2016 and certified that he does not have diabetic retinopathy. He
holds a Class A CDL from Illinois.

Mark W. Birch

    Mr. Birch, 46, has had ITDM since 2014. His endocrinologist
examined him in 2016 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Birch understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Birch meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
ophthalmologist examined him in 2016 and certified that he has stable
nonproliferative diabetic retinopathy. He holds a Class A CDL from
Texas.

Richard Bollhardt

    Mr. Bollhardt, 56, has had ITDM since 2013. His endocrinologist
examined him in 2016 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Bollhardt understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Bollhardt meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2016 and certified that he does not have
diabetic retinopathy. He holds an operator's license from New Jersey.

Bryan R. Breaw

    Mr. Breaw, 48, has had ITDM since 1987. His endocrinologist
examined him in 2016 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in

the last 5 years. His endocrinologist certifies that Mr. Breaw
understands diabetes management and monitoring, has stable control of
his diabetes using insulin, and is able to drive a CMV safely. Mr.
Breaw meets the requirements of the vision standard at 49 CFR
391.41(b)(10). His optometrist examined him in 2016 and certified that
he does not have diabetic retinopathy. He holds a Class A CDL from
Minnesota.

Trini L. Brisson

    Mr. Brisson, 48, has had ITDM since 2016. His endocrinologist
examined him in 2016 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Brisson understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Brisson meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2016 and certified that he does not have
diabetic retinopathy. He holds an operator's license from Michigan.

Keith M. Carpenter

    Mr. Carpenter, 51, has had ITDM since 2014. His endocrinologist
examined him in 2016 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Carpenter understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Carpenter meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2016 and certified that he does not have
diabetic retinopathy. He holds an operator's license from Pennsylvania.

Alan W. Carstensen

    Mr. Carstensen, 72, has had ITDM since 2014. His endocrinologist
examined him in 2016 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Carstensen understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Carstensen meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2016 and certified that he does not have
diabetic retinopathy. He holds a Class A CDL from Minnesota.

Russell L. Clapp

    Mr. Clapp, 56, has had ITDM since 2012. His endocrinologist
examined him in 2016 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Clapp understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Clapp meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2016 and certified that he does not have
diabetic retinopathy. He holds a Class B CDL from Maine.

Allan J. Clune

    Mr. Clune, 73, has had ITDM since 2013. His endocrinologist
examined him in 2016 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Clune understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Clune meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
ophthalmologist examined him in 2016 and certified that he does not
have diabetic retinopathy. He holds an operator's license from New
Jersey.

Ryan F. Curtis

    Mr. Curtis, 27, has had ITDM since 1996. His endocrinologist
examined him in 2016 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Curtis understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Curtis meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2016 and certified that he does not have
diabetic retinopathy. He holds an operator's license from New Jersey.

Jeffrey S. Daniels

    Mr. Daniels, 50, has had ITDM since 2013. His endocrinologist
examined him in 2016 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Daniels understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Daniels meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
ophthalmologist examined him in 2016 and certified that he has stable
nonproliferative diabetic retinopathy. He holds a Class C CDL from
Iowa.

Andrew M.M. Danner

    Mr. Danner, 21, has had ITDM since 2011. His endocrinologist
examined him in 2016 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Danner understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Danner meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2016 and certified that he does not have
diabetic retinopathy. He holds an operator's license from Virginia.

George P. Diedrich, Jr.

    Mr. Diedrich, 74, has had ITDM since 2016. His endocrinologist
examined him in 2016 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Diedrich understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Diedrich meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2016 and certified that he does not have
diabetic retinopathy. He holds a Class B CDL from New Jersey.

Wilson E. Donnell

    Mr. Donnell, 63, has had ITDM since 2016. His endocrinologist
examined him in 2016 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Donnell understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Donnell meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2016 and certified that he does not have
diabetic retinopathy. He holds a Class A CDL from Maine.

Michael W. Erick

    Mr. Erick, 62, has had ITDM since 2016. His endocrinologist
examined him in 2016 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Erick understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Erick meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2016 and certified that he does not have
diabetic retinopathy. He holds a Class A CDL from Connecticut.

Eric Fedor

    Mr. Fedor, 56, has had ITDM since 2016. His endocrinologist
examined him in 2016 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Fedor understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Fedor meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2016 and certified that he does not have
diabetic retinopathy. He holds a Class A CDL from Pennsylvania.

Juanita C. Gaines

    Ms. Gaines, 54, has had ITDM since 2002. Her endocrinologist
examined her in 2016 and certified that she has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
Her endocrinologist certifies that Ms. Gaines understands diabetes
management and monitoring has stable control of her diabetes using
insulin, and is able to drive a CMV safely. Ms. Gaines meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). Her
optometrist examined her in 2016 and certified that she does not have
diabetic retinopathy. She holds a Class B CDL from Texas.

Buckley E. Grant

    Mr. Grant, 44, has had ITDM since 2015. His endocrinologist
examined him in 2016 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Grant understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Grant meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2016 and certified that he does not have
diabetic retinopathy. He holds a Class A CDL from Kansas.

Connor J. Grossaint

    Mr. Grossaint, 23, has had ITDM since 2006. His endocrinologist
examined him in 2016 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Grossaint understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Grossaint meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2016 and certified that he does not have
diabetic retinopathy. He holds an operator's license from Utah.

Brian A. Hagenhoff

    Mr. Hagenhoff, 44, has had ITDM since 1989. His endocrinologist
examined him in 2016 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Hagenhoff understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Hagenhoff meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
ophthalmologist examined him in 2016 and certified that he has stable
nonproliferative diabetic retinopathy. He holds a Class A CDL from
Missouri.

Jeffrey D.S. Hosman

    Mr. Hosman, 23, has had ITDM since 1998. His endocrinologist
examined him in 2016 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Hosman understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV

safely. Mr. Hosman meets the requirements of the vision standard at 49
CFR 391.41(b)(10). His optometrist examined him in 2016 and certified
that he does not have diabetic retinopathy. He holds a Class B CDL from
Arkansas.

Terry P. Kelly

    Mr. Kelly, 50, has had ITDM since 2016. His endocrinologist
examined him in 2016 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Kelly understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Kelly meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2016 and certified that he does not have
diabetic retinopathy. He holds a Class D CDL from Kentucky.

David M. Kerr

    Mr. Kerr, 58, has had ITDM since 2016. His endocrinologist examined
him in 2016 and certified that he has had no severe hypoglycemic
reactions resulting in loss of consciousness, requiring the assistance
of another person, or resulting in impaired cognitive function that
occurred without warning in the past 12 months and no recurrent (2 or
more) severe hypoglycemic episodes in the last 5 years. His
endocrinologist certifies that Mr. Kerr understands diabetes management
and monitoring, has stable control of his diabetes using insulin, and
is able to drive a CMV safely. Mr. Kerr meets the requirements of the
vision standard at 49 CFR 391.41(b)(10). His optometrist examined him
in 2016 and certified that he does not have diabetic retinopathy. He
holds a Class A CDL from Pennsylvania.

Michael P. Kruimer

    Mr. Kruimer, 62, has had ITDM since 2012. His endocrinologist
examined him in 2016 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Kruimer understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Kruimer meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2016 and certified that he does not have
diabetic retinopathy. He holds a Class A CDL from New Jersey.

Salvatore Longo

    Mr. Longo, 45, has had ITDM since 2016. His endocrinologist
examined him in 2016 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Longo understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Longo meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2016 and certified that he does not have
diabetic retinopathy. He holds a Class A CDL from Illinois.

Alan Mills

    Mr. Mills, 62, has had ITDM since 2011. His endocrinologist
examined him in 2016 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Mills understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Mills meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
ophthalmologist examined him in 2016 and certified that he has stable
nonproliferative diabetic retinopathy. He holds a Class A CDL from
Oregon.

John R. Paulus

    Mr. Paulus, 69, has had ITDM since 1974. His endocrinologist
examined him in 2016 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Paulus understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Paulus meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2016 and certified that he does not have
diabetic retinopathy. He holds a Class A CDL from Wisconsin.

Bruce D. Peterson

    Mr. Peterson, 65, has had ITDM since 2016. His endocrinologist
examined him in 2016 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Peterson understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Peterson meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
ophthalmologist examined him in 2016 and certified that he has stable
nonproliferative diabetic retinopathy. He holds a Class A CDL from
Wisconsin.

Nicholas J. Powden

    Mr. Powden, 30, has had ITDM since 2015. His endocrinologist
examined him in 2016 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Powden understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Powden meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2016 and certified that he does not have
diabetic retinopathy. He holds an operator's license from Vermont.

Dennis A. Roisum

    Mr. Roisum, 59, has had ITDM since 2001. His endocrinologist
examined him in 2016 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or

more) severe hypoglycemic episodes in the last 5 years. His
endocrinologist certifies that Mr. Roisum understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Roisum meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
ophthalmologist examined him in 2016 and certified that he has stable
nonproliferative diabetic retinopathy. He holds an operator's license
from Wisconsin.

Jeffrey P. Roskopf

    Mr. Roskopf, 61, has had ITDM since 2016. His endocrinologist
examined him in 2016 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Roskopf understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Roskopf meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2016 and certified that he does not have
diabetic retinopathy. He holds a Class A CDL from Wisconsin.

David M. Ryea

    Mr. Ryea, 36, has had ITDM since 2001. His endocrinologist examined
him in 2016 and certified that he has had no severe hypoglycemic
reactions resulting in loss of consciousness, requiring the assistance
of another person, or resulting in impaired cognitive function that
occurred without warning in the past 12 months and no recurrent (2 or
more) severe hypoglycemic episodes in the last 5 years. His
endocrinologist certifies that Mr. Ryea understands diabetes management
and monitoring, has stable control of his diabetes using insulin, and
is able to drive a CMV safely. Mr. Ryea meets the requirements of the
vision standard at 49 CFR 391.41(b)(10). His optometrist examined him
in 2016 and certified that he does not have diabetic retinopathy. He
holds an operator's license from Connecticut.

Edward G. Smith, Jr.

    Mr. Smith, 58, has had ITDM since 2013. His endocrinologist
examined him in 2016 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Smith understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Smith meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2016 and certified that he does not have
diabetic retinopathy. He holds a Class A CDL from North Dakota.

Ralph H. Talmadge

    Mr. Talmadge, 71, has had ITDM since 2016. His endocrinologist
examined him in 2016 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Talmadge understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Talmadge meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2016 and certified that he does not have
diabetic retinopathy. He holds a Class B CDL from New Jersey.

Jerry R. Thomason

    Mr. Thomason, 57, has had ITDM since 2016. His endocrinologist
examined him in 2016 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Thomason understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Thomason meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2016 and certified that he does not have
diabetic retinopathy. He holds a Class A CDL from Georgia.

Melvin E. Turner

    Mr. Turner, 62, has had ITDM since 2015. His endocrinologist
examined him in 2016 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Turner understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Turner meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
ophthalmologist examined him in 2016 and certified that he does not
have diabetic retinopathy. He holds a Class A CDL from Tennessee.

Lash L. Walker

    Mr. Walker, 64, has had ITDM since 2006. His endocrinologist
examined him in 2016 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Walker understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Walker meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
ophthalmologist examined him in 2016 and certified that he has stable
nonproliferative and stable proliferative diabetic retinopathy. He
holds an operator's license from Tennessee.

Donald E. Walstrom

    Mr. Walstrom, 57, has had ITDM since 2016. His endocrinologist
examined him in 2016 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Walstrom understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Walstrom meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2016 and certified that he does not have
diabetic retinopathy. He holds a Class A CDL from Iowa.

Ronald A. Williams

    Mr. Williams, 66, has had ITDM since 2010. His endocrinologist
examined him in 2016 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Williams understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Williams meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2016 and certified that he does not have
diabetic retinopathy. He holds a Class A CDL from Oregon.

III. Request for Comments

    In accordance with 49 U.S.C. 31136(e) and 31315, FMCSA requests
public comment from all interested persons on the exemption petitions
described in this notice. We will consider all comments received before
the close of business on the closing date indicated in the date section
of the notice.
    FMCSA notes that section 4129 of the Safe, Accountable, Flexible
and Efficient Transportation Equity Act: A Legacy for Users requires
the Secretary to revise its diabetes exemption program established on
September 3, 2003 (68 FR 52441) \1\. The revision must provide for
individual assessment of drivers with diabetes mellitus, and be
consistent with the criteria described in section 4018 of the
Transportation Equity Act for the 21st Century (49 U.S.C. 31305).
---------------------------------------------------------------------------

    \1\ Section 4129(a) refers to the 2003 notice as a ``final
rule.'' However, the 2003 notice did not issue a ``final rule'' but
did establish the procedures and standards for issuing exemptions
for drivers with ITDM.
---------------------------------------------------------------------------

    Section 4129 requires: (1) Elimination of the requirement for 3
years of experience operating CMVs while being treated with insulin;
and (2) establishment of a specified minimum period of insulin use to
demonstrate stable control of diabetes before being allowed to operate
a CMV.
    In response to section 4129, FMCSA made immediate revisions to the
diabetes exemption program established by the September 3, 2003 notice.
FMCSA discontinued use of the 3-year driving experience and fulfilled
the requirements of section 4129 while continuing to ensure that
operation of CMVs by drivers with ITDM will achieve the requisite level
of safety required of all exemptions granted under 49 U.S.C.. 31136
(e).
    Section 4129(d) also directed FMCSA to ensure that drivers of CMVs
with ITDM are not held to a higher standard than other drivers, with
the exception of limited operating, monitoring and medical requirements
that are deemed medically necessary.
    The FMCSA concluded that all of the operating, monitoring and
medical requirements set out in the September 3, 2003 notice, except as
modified, were in compliance with section 4129(d). Therefore, all of
the requirements set out in the September 3, 2003 notice, except as
modified by the notice in the Federal Register on November 8, 2005 (70
FR 67777), remain in effect.

IV. Submitting Comments

    You may submit your comments and material online or by fax, mail,
or hand delivery, but please use only one of these means. FMCSA
recommends that you include your name and a mailing address, an email
address, or a phone number in the body of your document so that FMCSA
can contact you if there are questions regarding your submission.
    To submit your comment online, go to http://www.regulations.gov and
in the search box insert the docket number FMCSA-2016-0381 and click
the search button. When the new screen appears, click on the blue
``Comment Now!'' button on the right hand side of the page. On the new
page, enter information required including the specific section of this
document to which each comment applies, and provide a reason for each
suggestion or recommendation. If you submit your comments by mail or
hand delivery, submit them in an unbound format, no larger than 8\1/2\
by 11 inches, suitable for copying and electronic filing. If you submit
comments by mail and would like to know that they reached the facility,
please enclose a stamped, self-addressed postcard or envelope.
    We will consider all comments and material received during the
comment period. FMCSA may issue a final determination at any time after
the close of the comment period.

V. Viewing Comments and Documents

    To view comments, as well as any documents mentioned in this
preamble, go to http://www.regulations.gov and in the search box insert
the docket number FMCSA-2016-0381 and click ``Search.'' Next, click
``Open Docket Folder'' and you will find all documents and comments
related to this notice.

    Issued on: December 19, 2016.
Larry W. Minor,
 Associate Administrator for Policy.
[FR Doc. 2016-31546 Filed 12-28-16; 8:45 am]
 BILLING CODE 4910-EX-P


[Federal Register Volume 78, Number 209 (Tuesday, October 29, 2013)]
[Notices]
[Pages 64486-64488]
[FR Doc No: 2013-25528]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

Combined Notice of Filings 1

    Take notice that the Commission received the following electric
corporate filings:

    Docket Numbers: EC14-9-000.
    Applicants: Lower Mount Bethel Energy, LLC.
    Description: Section 203 Application of Lower Mount Bethel Energy,
LLC.
    Filed Date: 10/18/13.
    Accession Number: 20131018-5191.
    Comments Due: 5 p.m. ET 11/8/13.

    Take notice that the Commission received the following exempt
wholesale generator filings:

    Docket Numbers: EG14-8-000.

    Applicants: Yellow Jacket Energy, LLC.
    Description: Notice of Self-Certification of Exempt Wholesale
Generator Status of Yellow Jacket Energy, LLC.
    Filed Date: 10/18/13.
    Accession Number: 20131018-5148.
    Comments Due: 5 p.m. ET 11/8/13.

    Take notice that the Commission received the following electric
rate filings:

    Docket Numbers: ER10-1246-004; ER10-1982-005; ER10-1253-004; ER10-
1252-004; ER13-764-004; ER12-2498-004; ER12-2499-004.
    Applicants: Consolidated Edison Energy, Inc., Consolidated Edison
Solutions, Inc., Consolidated Edison Company of New York, Inc., Orange
and Rockland Utilities, Inc., CED White River Solar, LLC, Alpaugh 50,
LLC, Alpaugh North, LLC.
    Description: Notice of non-material change status of Consolidated
Edison Energy, Inc., et al.
    Filed Date: 10/21/13.
    Accession Number: 20131021-5055.
    Comments Due: 5 p.m. ET 11/12/13.

    Docket Numbers: ER10-2374-004; ER10-1533-005.
    Applicants: Puget Sound Energy, Inc., Macquarie Energy LLC.
    Description: Amendment to June 28, 2013 Triennial Updated Market
Power Analysis in the Northwest Region of Puget Sound Energy, Inc., et
al.
    Filed Date: 10/18/13.
    Accession Number: 20131018-5195.
    Comments Due: 5 p.m. ET 11/8/13.

    Docket Numbers: ER11-3262-002.
    Applicants: Trans Bay Cable LLC.
    Description: Response to September 19, 2013 Data Request Letter,
Docket ER11-3262-002 to be effective N/A.
    Filed Date: 10/21/13.
    Accession Number: 20131021-5003.
    Comments Due: 5 p.m. ET 11/12/13.

    Docket Number: ER13-2225-001.
    Applicants: Entergy Arkansas, Inc.
    Description: Amendment to EWOM NITSA to be effective 5/1/2013.
    Filed Date: 10/21/13.
    Accession Number: 20131021-5000.
    Comments Due: 5 p.m. ET 11/12/13.

    Docket Numbers: ER14-128-000.
    Applicants: Entergy Texas, Inc.
    Description: ETI Notice of Cancellation of System Agreement to be
effective 10/18/2018.
    Filed Date: 10/18/13.
    Accession Number: 20131018-5159.
    Comments Due: 5 p.m. ET 11/8/13.

    Docket Numbers: ER14-129-000.
    Applicants: Entergy Gulf States Louisiana, L.L.C.
    Description: Wholesale Distribution Service Tariff to be effective
12/19/2013.
    Filed Date: 10/18/13.
    Accession Number: 20131018-5161.
    Comments Due: 5 p.m. ET 11/8/13.

    Docket Numbers: ER14-130-000.
    Applicants: Entergy Louisiana, LLC.
    Description: Wholesale Distribution Service Tariff to be effective
12/19/2013.
    Filed Date: 10/18/13.
    Accession Number: 20131018-5164.
    Comments Due: 5 p.m. ET 11/8/13.

    Docket Numbers: ER14-131-000.
    Applicants: Entergy Mississippi, Inc.
    Description: Wholesale Distribution Service Tariff to be effective
12/19/2013.
    Filed Date: 10/18/13.
    Accession Number: 20131018-5166.
    Comments Due: 5 p.m. ET 11/8/13.

    Docket Numbers: ER14-132-000.
    Applicants: Entergy Texas, Inc.
    Description: Wholesale Distribution Service Tariff to be effective
12/19/2013.
    Filed Date: 10/18/13.
    Accession Number: 20131018-5167.
    Comments Due: 5 p.m. ET 11/8/13.

    Docket Numbers: ER14-133-000.
    Applicants: Entergy Arkansas, Inc.
    Description: WDS and LBA Agreements with AECC to be effective 12/
19/2013.
    Filed Date: 10/18/13.
    Accession Number: 20131018-5169.
    Comments Due: 5 p.m. ET 11/8/13.

    Docket Numbers: ER14-134-000.
    Applicants: Entergy Arkansas, Inc.
    Description: EAI Cert Concurrence to MISO Coordination Agreement to
be effective 12/19/2013.
    Filed Date: 10/18/13.
    Accession Number: 20131018-5173.
    Comments Due: 5 p.m. ET 11/8/13.

    Docket Numbers: ER14-135-000.
    Applicants: Cleco Power LLC.
    Description: Cleco WDS and Service Agreements to be effective 12/
19/2013.
    Filed Date: 10/21/13.
    Accession Number: 20131021-5006.
    Comments Due: 5 p.m. ET 11/12/13.

    Docket Numbers: ER14-136-000.
    Applicants: Midcontinent Independent System Operator, Inc.
    Description: Midcontinent Independent System Operator, Inc. submits
filing outlining the market power analysis recommendations of the
Independent Market Monitor performed pursuant to Section 63.4.1.g of
MISO's Tariff.
    Filed Date: 10/18/13.
    Accession Number: 20131018-5196.
    Comments Due: 5 p.m. ET 11/8/13.

    Docket Numbers: ER14-137-000.
    Applicants: Duke Energy Progress, Inc.
    Description: Cancellation of Duke Energy Progress, Inc. OATT to be
effective 12/20/2013 under ER14-137 Filing Type: 410.
    Filed Date: 10/21/13.
    Accession Number: 20131021-5034.
    Comments Due: 5 p.m. ET 11/12/13.

    Docket Numbers: ER14-138-000.
    Applicants: Duke Energy Progress, Inc.
    Description: OATT Name Change to be effective 12/20/201.
    Filed Date: 10/21/13.
    Accession Number: 20131021-5035.
    Comments Due: 5 p.m. ET 11/12/13.

    Docket Numbers: ER14-139-000.
    Applicants: ArcLight Energy Marketing, LLC.
    Description: ArcLight Energy Marketing, LLC submits AEM CIS and
Tariff Revisions to be effective 12/20/2013.
    Filed Date: 10/21/13.
    Accession Number: 20131021-5068.
    Comments Due: 5 p.m. ET 11/12/13.

    Docket Numbers: ER14-140-000.
    Applicants: Panther Creek Power Operating, LLC.
    Description: Panther Creek Power Operating, LLC submits Panther
Tariff Revisions to be effective 12/20/2013.
    Filed Date: 10/21/13.
    Accession Number: 20131021-5069.
    Comments Due: 5 p.m. ET 11/12/13.

    Docket Numbers: ER14-141-000.
    Applicants: Scrubgrass Generating Company, L.P.
    Description: Scrubgrass Generating Company, L.P. submits Scrubgrass
CIS & Tariff Revisions to be effective 12/20/2013.
    Filed Date: 10/21/13.
    Accession Number: 20131021-5094.
    Comments Due: 5 p.m. ET 11/12/13.

    Docket Numbers: ER14-142-000.
    Applicants: Ameren Energy Generating Company.
    Description: Ameren Energy Generating Company submits Notice of
Cancellation and Amendment Filing to be effective 10/11/2013.
    Filed Date: 10/21/13.
    Accession Number: 20131021-5102.
    Comments Due: 5 p.m. ET 11/12/13.

    Docket Numbers: ER14-143-000.
    Applicants: AmerenEnergy Medina Valley Cogen, L.L.C.
    Description: AmerenEnergy Medina Valley Cogen, L.L.C. submits
Notice of Succession to be effective 10/11/2013.
    Filed Date: 10/21/13.
    Accession Number: 20131021-5105.
    Comments Due: 5 p.m. ET 11/12/13.

    The filings are accessible in the Commission's eLibrary system by
clicking on the links or querying the docket number.
    Any person desiring to intervene or protest in any of the above
proceedings must file in accordance with Rules 211 and 214 of the
Commission's

Regulations (18 CFR 385.211 and 385.214) on or before 5:00 p.m. Eastern
time on the specified comment date. Protests may be considered, but
intervention is necessary to become a party to the proceeding.
    eFiling is encouraged. More detailed information relating to filing
requirements, interventions, protests, service, and qualifying
facilities filings can be found at: http://www.ferc.gov/docs-filing/efiling/filing-req.pdf. For other information, call<PHONE_NUMBER>
(toll free). For TTY, call<PHONE_NUMBER>.

    Dated: October 21, 2013.
Nathaniel J. Davis, Sr.,
Deputy Secretary.
[FR Doc. 2013-25528 Filed 10-28-13; 8:45 am]
BILLING CODE 6717-01-P


  MacroButton macIb01 i

EPA BIOPESTICIDES AND POLLUTION PREVENTION DIVISION COMPANY NOTICE OF
FILING FOR PESTICIDE PETITIONS PUBLISHED IN THE FEDERAL REGISTER

EPA Biopesticides and Pollution Prevention Division contact: [Kimberly
Nesci;<PHONE_NUMBER>]

INSTRUCTIONS:  Please utilize this outline in preparing the pesticide
petition.  In cases where the outline element does not apply, please
insert “NA-Remove” and maintain the outline. Please do not change
the margins, font, or format in your pesticide petition. Simply replace
the instructions that appear in green, i.e., “[insert company
name],” with the information specific to your action.

SUBMISSION:

TEMPLATE:

[Anatis Bioprotection Inc.]

[PP 3F8176]

	EPA has received a pesticide petition ([PP 3F8176]) from [Anatis
Bioprotection Inc. (EPA Company No. 89600)], [278, rang Saint-André,
St-Jacques-le-Mineur, Quebec J0J 1Z0, Canada] requesting, pursuant to
section 408(d) of the Federal Food, Drug, and Cosmetic Act (FFDCA), 21
U.S.C. 346a(d), to amend 40 CFR part 180 to establish an exemption from
the requirement of a tolerance for microbial pesticide  [Beauveria
bassiana strain ANT-03].

Pursuant to section 408(d)(2)(A)(i) of  FFDCA, as amended, [Anatis
Bioprotection Inc.] has submitted the following summary of information,
data, and arguments in support of their pesticide petition. This summary
was prepared by [Anatis Bioprotection Inc.] and EPA has not fully
evaluated the merits of the pesticide petition. The summary may have
been edited by EPA if the terminology used was unclear, the summary
contained extraneous material, or the summary unintentionally made the
reader conclude that the findings reflected EPA’s position and not the
position of the petitioner.

I. [Anatis Bioprotection Inc.] Petition Summary

	[PP 3F8176]

A. Product Name and Proposed Use Practices

	[Beauveria bassiana strain ANT-03 Technical, a Technical Grade Active
Ingredient (TGAI) is proposed for manufacturing use only, for further
formulation into registered end-use products.

	Bioceres is a biological insecticide containing the active ingredient
Beauveria bassiana strain ANT-03 for use on growing crops to control
insect pests. Bioceres acts as a contact biological insecticide for use
in the control or suppression of many foliar-feeding pests, including
aphids, whiteflies, thrips, plant bugs, beetles and weevils infesting
labeled crops or use sites. Bioceres must be mixed with water and
applied as a foliar spray with ground or aerial equipment equipped for
conventional insecticide spraying, or by chemigation, in field,
greenhouse, turf and ornamental or home and garden use sites.]

B. Product Identity/Chemistry

	1. Identity of the pesticide and corresponding residues. [Beauveria
bassiana strain ANT-03 (CAS No. Not applicable).

	Information regarding the name, identity and composition has been
submitted to EPA and can be found in MRID Nos. 489472-01 and 489472-02.

	Beauveria bassiana is a ubiquitous entomopathogenic fungus that has
been found in environments around the world.  There is a significant
body of published literature on this microbial pest control agent (MPCA)
with regards to its identification, occurrence, life cycle, pest host
range, mode of action, persistence, efficaciousness, and safety to
mammals and nontarget organisms.  Relevant literature is summarized or
referenced in MRID Nos. 489472-01, 489472-12 and 489472-13.  Beauveria
bassiana strain ANT-03 spores attach to the surface of the target insect
pest, germinate, penetrate the exoskeleton and grow rapidly resulting in
death of the insect host (MRID No. 489472-01).]

	2. Magnitude of residues at the time of harvest and method used to
determine the residue. [An analytical method for residues is not
applicable.  It is expected that, when used as proposed, Beauveria
bassiana strain ANT-03, would not result in residues that are of
toxicological concern.]

	3. A statement of why an analytical method of detecting and measuring
the levels of the pesticide residue are not needed. [NA-Remove]

C. Mammalian Toxicological Profile

	[Studies to evaluate the safety to mammals were conducted on the
technical grade active ingredient (TGAI) and are summarized as follows:

Acute Oral Toxicity/Pathogenicity Study in Rats (OCSPP 885.3050):
Beauveria bassiana strain ANT-03 Technical (the Microbial Pest Control
Agent or MPCA) was tested in a single high dose exposure in an acute
oral toxicity/pathogenicity study in rats, and there were no signs of
toxicity or infectivity from exposure to test material (MRID No.
489742-03).  There was no mortality during the study and all animals
appeared normal during the duration of the study.  No observable
abnormalities were reported at necropsy.

	The MPCA test substance and inactivated MPCA test substance was
administered to rats by gavage in a single high dose. The animals were
observed frequently on the day of dosing (Day 0) for mortality and signs
of pharmacologic and/or toxicologic effects and once daily thereafter
for 21 days. A control group (untreated) was conducted concurrently. The
test organism had cleared completely from the Group IV blood, lungs,
liver, kidneys, mesenteric lymph nodes and cecum contents by Day 14 and
had cleared completely from the brain and spleen by Day 21. After two
consecutive interim sacrifices showed no growth of test organism in the
organs plated, no further tissue samples were taken. The test substance
was determined to be non-toxic to rats when administered by oral gavage
in a single dose of 1.3 x 109 CFU/rat.

Acute Pulmonary Toxicity/Pathogenicity Study in Rats (OCSPP 885.3150):
Beauveria bassiana strain ANT-03 Technical (the Microbial Pest Control
Agent or MPCA) was tested in a single high dose exposure in an acute
pulmonary toxicity/pathogenicity study in rats, and there were no signs
of toxicity or infectivity from exposure to test material (MRID No.
489742-04).  There was no mortality during the study and all animals
appeared normal during the duration of the study.  No observable
abnormalities were reported at necropsy.

The MPCA test substance and inactivated MPCA test substance was
administered to rats by tracheal gavage in a single high dose. The
animals were observed frequently on the day of dosing (Day 0) for
mortality and signs of pharmacologic and/or toxicologic effects and once
daily thereafter for 21 days. A control group (untreated) was conducted
concurrently. The test organism was not seen at any time from the Group
IV - MPCA blood, kidneys, mesenteric lymph nodes, brain, liver, spleen
and cecum contents. Except for the Day 0 sacrifice, the test substance
was not seen in the lungs at any time. After two consecutive interim
sacrifices showed no growth of the test substance in the organs plated,
no further tissue samples were taken. The test substance was determined
to be non-toxic to rats when administered by tracheal gavage in a single
dose of 1.1 x 109 CFU/rat.

Acute IP Toxicity/Pathogenicity Study in Rats (OCSPP 885.320):  In the
IP study, the MPCA test substance and inactivated MPCA test substance
were administered to rats by intraperitonial injection in a single high
dose (MRID No. 489742-05).  The animals were observed frequently on day
of dosing for mortality and signs of pharmacologic and/or toxicologic
effects and once daily thereafter for 21 days. Control groups (untreated
and inactive) were conducted concurrently. A gross necropsy of all
animals was performed and recorded. There were no mortalities and no
abnormal general health findings. The test substance  was determined to
be non-toxic to rats when administered by IP injection at a single dose
of 1.4 x 109 CFU/rat.

Acute Dermal Toxicity (OCSPP 870.1200): Beauveria bassiana strain ANT-03
Technical (the Microbial Pest Control Agent or MPCA) was tested in a
single high dose exposure in an acute dermal toxicity study in rats, and
there were no signs of toxicity or dermal irritation from exposure to
test material (MRID No. 489742-06).  The MPCA test substance was
evaluated for its dermal toxicity potential and relative skin irritancy
when a single dose moistened with 1.0 mL of deionized (DI) water/g test
substance, at a level of 5050 mg/kg, was applied to the intact skin of
albino rats. No mortality occurred. There were no clinical signs of
toxicity or signs of dermal irritation at any time throughout the study.
Animals exhibited weekly weight gain during the study. The gross
necropsy conducted at termination of the study revealed no observable
abnormalities. The estimated LD50, as indicated by the data, was
determined to be greater than 5050 mg/kg.

5.	Hypersensitivity Incidents (OCSPP 885.3400):   The registrant has
noted that no incidents of hypersensitivity or any other adverse effects
have occurred through the research, development or testing of the active
ingredient and its related end-use product.  Should any incidents occur,
they will be reported per FIFRA Section 6(a)(2).

Rationales for no further testing have been submitted for acute oral
toxicity (limit), acute inhalation toxicity (limit), primary eye
irritation and primary dermal irritation data requirements on Beauveria
bassiana strain ANT-03 Technical (MRID No. 489742-13).  Rationales are
based on discussions of existing data and, in the case of the primary
eye irritation requirement, mitigating label language.

Data has been generated and submitted to demonstrate that Beauveria
bassiana strain ANT-03 does not produce unintentional ingredients such
as toxic metabolites (beauvericin) or microbial contaminants (MRID Nos.
489742-01 and 489742-02).

In conclusion, the results of toxicity testing show there is no risk to
human health from the active ingredient.  Beauveria bassiana strain
ANT-03 is not toxic, pathogenic, infective or irritating to mammals.]

D. Aggregate Exposure

	1. Dietary exposure.

	i. Food. [Dietary exposure from use of Beauveria bassiana strain
ANT-03, as proposed, is minimal.  The intended use of Beauveria bassiana
strain ANT-03 is as a biological insecticide to growing plants in
agricultural, greenhouse, turf and ornamental and home and garden use
sites.  Data in published literature demonstrate that Beauveria bassiana
does not persist in the environment following application.
Environmental conditions such as UV-radiation, air temperature and
rainfall are factors that lead to a short life in field conditions (MRID
No. 489742-12).

	The results of toxicity testing indicate there is no risk to human
health or the environment from Beauveria bassiana strain ANT-03.
Beauveria bassiana strain ANT-03 does not produce recognized toxins,
enzymes, or virulence factors normally associated with mammalian
invasiveness or toxicity.  The absence of acute toxicity or
pathogenicity in laboratory animals demonstrates the benign nature of
this strain.]

	ii. Drinking water. [Similarly, exposure to humans from residues of
Beauveria bassiana strain ANT-03 in consumed drinking water would be
unlikely.  Potential exposure to surface water would be negligible and
exposure to drinking water (well or ground water) would be impossible to
measure. The intended use of Beauveria bassiana strain ANT-03 is as a
biological insecticide to growing plants in agricultural, greenhouse,
turf and ornamental and home and garden use sites.  Data in published
literature demonstrate that Beauveria bassiana does not persist in the
environment following application.  Environmental conditions such as
UV-radiation, air temperature and rainfall are factors that lead to a
short life in field conditions.  The risk of the microorganism passing
through the soil to ground water is minimal to unlikely.  Additionally
the fungus would not tolerate the conditions water is subjected to in a
drinking-water facility (including:  chlorination, pH adjustments, high
temperatures and/or anaerobic conditions).

	The results of toxicity testing indicate there is no risk to human
health or the environment from Beauveria bassiana strain ANT-03.
Beauveria bassiana strain ANT-03 does not produce recognized toxins,
enzymes, or virulence factors normally associated with mammalian
invasiveness or toxicity.  The absence of acute toxicity or
pathogenicity in laboratory animals demonstrates the benign nature of
this strain.]

	2. Non-dietary exposure. [The potential for non-dietary exposure to the
general population, including infants and children, is unlikely as the
proposed use sites are agricultural.  The intended use of Beauveria
bassiana strain ANT-03 is as a biological insecticide to growing plants
in agricultural, greenhouse, turf and ornamental and home and garden use
sites.  Data in published literature demonstrate that Beauveria bassiana
does not persist in the environment following application.
Environmental conditions such as UV-radiation, air temperature and
rainfall are factors that lead to a short life in field conditions.
Personal Protective Equipment (PPE) mitigates the potential for exposure
to applicators and handlers of the proposed products, when used in
agricultural settings.

	The results of toxicity testing indicate there is no risk to human
health or the environment from Beauveria bassiana strain ANT-03.
Beauveria bassiana strain ANT-03 does not produce recognized toxins,
enzymes, or virulence factors normally associated with mammalian
invasiveness or toxicity.  The absence of acute toxicity or
pathogenicity in laboratory animals demonstrates the benign nature of
this strain.  Non-dietary exposures would not be expected to pose any
quantifiable risk due to a lack of residues of toxicological concern.]

E. Cumulative Effects

	[It is not expected that, when used as proposed, Beauveria bassiana
strain ANT-03 would result in residues that are of toxicological
concern. The intended use of Beauveria bassiana strain ANT-03 is as a
biological insecticide to growing plants in agricultural, greenhouse,
turf and ornamental and home and garden use sites.  Data in published
literature demonstrate that Beauveria bassiana does not persist in the
environment following application.  Environmental conditions such as
UV-radiation, air temperature and rainfall are factors that lead to a
short life in field conditions.  The results of toxicity testing
indicate there is no risk to human health or the environment from
Beauveria bassiana strain ANT-03. Beauveria bassiana strain ANT-03 does
not produce recognized toxins, enzymes, or virulence factors normally
associated with mammalian invasiveness or toxicity.  The absence of
acute toxicity or pathogenicity in laboratory animals demonstrates the
benign nature of this strain.]

F. Safety Determination

	1. U.S. population. [Acute toxicity studies have shown that Beauveria
bassiana strain ANT-03 is not toxic, pathogenic, infective or irritating
to mammals.  The intended use of Beauveria bassiana strain ANT-03 is as
a biological insecticide to growing plants in agricultural, greenhouse,
turf and ornamental and home and garden use sites.  Data in published
literature demonstrate that Beauveria bassiana does not persist in the
environment following application.  Environmental conditions such as
UV-radiation, air temperature and rainfall are factors that lead to a
short life in field conditions.  The results of toxicity testing
indicate there is no risk to human health or the environment from
Beauveria bassiana strain ANT-03. Beauveria bassiana strain ANT-03 does
not produce recognized toxins, enzymes, or virulence factors normally
associated with mammalian invasiveness or toxicity.  The absence of
acute toxicity or pathogenicity in laboratory animals demonstrates the
benign nature of this strain.  There is a reasonable certainty of no
harm to the general US population from exposure to this active
ingredient.]

	2. Infants and children. [As mentioned above, it is not expected that,
when used as proposed, Beauveria bassiana strain ANT-03 would result in
residues that are of toxicological concern. There is a reasonable
certainty of no harm for infants and children from exposure to Beauveria
bassiana strain ANT-03 from the proposed uses.]

G. Effects on the Immune and Endocrine Systems

	[To date there is no evidence to suggest that Beauveria bassiana strain
ANT-03 functions in a manner similar to any known hormone, or that it
acts as an endocrine disrupter.]

H. Existing Tolerances

	[There is no US EPA tolerance or tolerance exemption for Beauveria
bassiana strain ANT-03.]

I. International Tolerances

	[A Codex Alimentarium Commission Maximum Residue Level (MRL) is not
established for Beauveria bassiana strain ANT-03.]

 PAGE

 PAGE   3


[Federal Register Volume 81, Number 62 (Thursday, March 31, 2016)]
[Notices]
[Page 18622]
[FR Doc No: 2016-07232]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

Notice of Technical Conference

------------------------------------------------------------------------
                                                             Project No.
------------------------------------------------------------------------
FFP Missouri 12, LLC.......................................    13755-002
FFP Missouri 5, LLC........................................    13757-002
FFP Missouri 6, LLC........................................    13761-002
Solia 6 Hydroelectric, LLC.................................    13768-002
------------------------------------------------------------------------

    On Wednesday, April 6, 2016, Commission staff will hold a technical
conference to discuss cultural resources related to Rye Development,
LLC's proposed Allegheny Lock and Dam No. 2 Hydroelectric Project No.
13755, Emsworth Locks and Dam Hydroelectric Project No. 13757, Emsworth
Back Channel Dam Hydroelectric Project No. 13761, and Montgomery Locks
and Dam Hydroelectric Project No. 13768.
    The technical conference will begin at 2:00 p.m. Eastern Standard
Time. The conference will be held at the Federal Energy Regulatory
Commission headquarters building located at 888 1st Street NE.,
Washington, DC, and will include teleconference capabilities.
    All local, state, and federal agencies, Indian tribes, and other
interested parties are invited to participate. There will be no
transcript of the conference, but a summary of the meeting will be
prepared for the project record. If you are interested in participating
in the meeting you must contact Allyson Conner at<PHONE_NUMBER> or
<EMAIL_ADDRESS>by April 4, 2016 to receive specific
instructions on how to participate.

    Dated: March 22, 2016.
Nathaniel J. Davis, Sr.,
Deputy Secretary.
[FR Doc. 2016-07232 Filed 3-30-16; 8:45 am]
 BILLING CODE 6717-01-P


[Federal Register Volume 87, Number 124 (Wednesday, June 29, 2022)]
[Notices]
[Pages 38742-38743]
[FR Doc No: 2022-13884]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

Combined Notice of Filings #1

    Take notice that the Commission received the following electric
corporate filings:

    Docket Numbers: EC22-80-000.
    Applicants: Capistrano Portfolio Holdco LLC, Broken Bow Wind, LLC,
Crofton Bluffs Wind, LLC, Mountain Wind Power, LLC, Mountain Wind Power
II LLC.
    Description: Joint Application for Authorization Under Section 203
of the Federal Power Act of Capistrano Portfolio Holdco LLC, et al.
    Filed Date: 6/23/22.
    Accession Number: 20220623-5159.
    Comment Date: 5 p.m. ET 7/14/22.

    Take notice that the Commission received the following electric
rate filings:

    Docket Numbers: ER19-1553-000.
    Applicants: Southern California Edison Company.
    Description: Southern California Edison Company's (SCE)Errata
Notice of Intent to Revise SCE's Formula Transmission Rate Annual
Update TO2021 and TO2022.
    Filed Date: 6/22/22.
    Accession Number: 20220622-5140.
    Comment Date: 5 p.m. ET 7/13/22.

    Docket Numbers: ER22-69-001.
    Applicants: Indeck Niles, LLC.
    Description: Compliance filing: Amended Notice of Change in Status
& Change in Seller Category (ER22-69-) to be effective N/A.
    Filed Date: 6/23/22.
    Accession Number: 20220623-5030.
    Comment Date: 5 p.m. ET 7/14/22.

    Docket Numbers: ER22-1743-001.
    Applicants: Indeck Corinth Limited Partnership.
    Description: Tariff Amendment: Amended Notice of Change in Status &
Seller Category Designation (ER22-1743) to be effective 5/2/2022.
    Filed Date:6/23/22.
    Accession Number: 20220623-5045.
    Comment Date: 5 p.m. ET 7/14/22.

    Docket Numbers: ER22-1744-001.
    Applicants: Indeck Energy Services of Silver Springs, Inc.
    Description: Tariff Amendment: Amended Notice of Change in Status &
Seller Category Designation (ER22-1744) to be effective 5/2/2022.
    Filed Date: 6/23/22.
    Accession Number: 20220623-5031.
    Comment Date: 5 p.m. ET 7/14/22.

    Docket Numbers: ER22-1745-001.
    Applicants: Indeck-Olean Limited Partnership.
    Description: Tariff Amendment: Amended Notice of Change in Status &
Seller Category Designation (ER22-1745) to be effective 5/2/2022.
    Filed Date: 6/23/22.
    Accession Number: 20220623-5039.
    Comment Date: 5 p.m. ET 7/14/22.

    Docket Numbers: ER22-1748-001.
    Applicants: Indeck-Oswego Limited Partnership.
    Description: Tariff Amendment: Amended Notice of Change in Status &
Seller Category Designation (ER22-1748) to be effective 5/2/2022.
    Filed Date: 6/23/22.
    Accession Number: 20220623-5044.
    Comment Date: 5 p.m. ET 7/14/22.

    Docket Numbers: ER22-1751-001.
    Applicants: Indeck-Yerkes Limited Partnership.
    Description: Tariff Amendment: Amended Notice of Change in Status &
Seller Category Designation (ER22-1751) to be effective 5/2/2022.
    Filed Date: 6/23/22.
    Accession Number: 20220623-5042.
    Comment Date: 5 p.m. ET 7/14/22.

    Docket Numbers: ER22-2176-000.
    Applicants: Rolling Hills Generating, L.L.C.
    Description: Compliance filing: eTariff Baseline Filing to be
effective 6/24/2022.
    Filed Date: 6/23/22.
    Accession Number: 20220623-5094.
    Comment Date: 5 p.m. ET 7/14/22.

    Docket Numbers: ER22-2176-001.
    Applicants: Rolling Hills Generating, L.L.C.
    Description: Compliance filing: Informational Filing Pursuant to
Schedule 2 of the PJM OATT & Request for Waiver to be effective N/A.
    Filed Date: 6/23/22.
    Accession Number: 20220623-5148.
    Comment Date: 5 p.m. ET 7/14/22.

    Docket Numbers: ER22-2177-000.
    Applicants: American Electric Power Service Corporation, Ohio Power
Company, PJM Interconnection, L.L.C.
    Description: Sec.  205(d) Rate Filing: American Electric Power
Service Corporation submits tariff filing per 35.13(a)(2)(iii: AEP
submits revised SA No. 1422 OPCo-Deshler ILDSA to be effective 5/1/
2022.
    Filed Date: 6/23/22.
    Accession Number: 20220623-5120.
    Comment Date: 5 p.m. ET 7/14/22.

    Docket Numbers: ER22-2178-000.
    Applicants: ORNI 50 LLC.
    Description: Baseline eTariff Filing: Petition for Approval of
Initial Market-Based Rate Tariff to be effective 6/24/2022.
    Filed Date: 6/23/22.
    Accession Number: 20220623-5122.
    Comment Date: 5 p.m. ET 7/14/22.

    Docket Numbers: ER22-2179-000.
    Applicants: PacifiCorp.
    Description: Sec.  205(d) Rate Filing: UMPA Const Agmt Nephi to be
effective 8/23/2022.

    Filed Date: 6/23/22.
    Accession Number: 20220623-5145.
    Comment Date: 5 p.m. ET 7/14/22.
    The filings are accessible in the Commission's eLibrary system
(https://elibrary.ferc.gov/idmws/search/fercgensearch.asp) by querying
the docket number.
    Any person desiring to intervene or protest in any of the above
proceedings must file in accordance with Rules 211 and 214 of the
Commission's Regulations (18 CFR 385.211 and 385.214) on or before 5:00
p.m. Eastern time on the specified comment date. Protests may be
considered, but intervention is necessary to become a party to the
proceeding.
    eFiling is encouraged. More detailed information relating to filing
requirements, interventions, protests, service, and qualifying
facilities filings can be found at: http://www.ferc.gov/docs-filing/efiling/filing-req.pdf. For other information, call<PHONE_NUMBER>
(toll free). For TTY, call<PHONE_NUMBER>.

    Dated: June 23, 2022.
Debbie-Anne A. Reese,
Deputy Secretary.
[FR Doc. 2022-13884 Filed 6-28-22; 8:45 am]
BILLING CODE 6717-01-P